Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma - Trial NCT05927610
Access comprehensive clinical trial information for NCT05927610 through Pure Global AI's free database. This phase not specified trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Glioblastoma. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Memorial Sloan Kettering Cancer Center
Timeline & Enrollment
N/A
Jun 19, 2023
Jun 19, 2028
Primary Outcome
Overall Survival
Summary
The goal of this study is to determine the utility of cerebrospinal fluid (CSF) cell-free DNA
 (cfDNA) as a prognostic biomarker in glioblastoma (GBM).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05927610
Non-Device Trial